Steve Anderson

Want to write for Entrepreneur too? Apply to join Entrepreneur Leadership network.

More From Steve Anderson

Business News

Time to Join Sorrento Therapeutics on its Next Leg Up

We've heard from Sorrento Therapeutics (NASDAQ:SRNE) before, and usually, things are looking good for the biotechnology industry firm. While it's never been a big player—share prices haven't broken the $15 price point in the last five years

More Authors You Might Like